Vivani Medical (VANI) Price & Analysis

Compare

807 Followers

VANI Stock Chart & Stats

$1.28

-$0.02(-1.59%)

At close: Jan 08 4:00 PM EST

$1.28

-$0.02(-1.59%)

Day’s Range― - ―

52-Week Range$0.91 - $1.92

Previous CloseN/A

Volume36.09K

Average Volume (3M)216.92K

Market Cap

$83.90M

Enterprise Value$83.60M

Total Cash (Recent Filing)$2.63M

Total Debt (Recent Filing)$18.29M

Price to Earnings (P/E)―

Beta1.18

Next Earnings

Mar 26, 2026

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.11

Shares Outstanding72,952,230

10 Day Avg. Volume237,036

30 Day Avg. Volume216,922

Financial Highlights & Ratios

PEG Ratio0.19

Price to Book (P/B)3.62

Price to Sales (P/S)0.00

P/FCF Ratio-2.99

Enterprise Value/Market Cap1.00

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-430.95

Enterprise Value/Ebitda-3.18

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.36

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentAnalyst notes Vivani Medical is preparing to initiate clinical development of NPM-139 for chronic weight management in obese or overweight patients with related comorbidities, offering a pathway to demonstrate human efficacy.

Preclinical EfficacyAnalyst highlights that NPM-139 produced roughly 20% body-weight reduction in animal studies, suggesting promising efficacy that could be competitive with marketed GLP-1 therapies.

Safety And TolerabilityAnalyst suggests NPM-139 may provide an improved safety and tolerability profile versus marketed semaglutide, which could lower therapy discontinuation and enhance patient adherence.

Bears Say

Development Timeline RiskAnalyst indicates that funding uncertainty could delay planned clinical activities and slow progress toward key development milestones.

Dilution RiskAnalyst notes that any required equity financing could dilute existing shareholders, reducing per-share value if new shares are issued.

Near-term Funding NeedAnalyst warns the company may need to raise additional capital in the near term, creating financing uncertainty that could pressure the stock.

Vivani Medical News

Vivani’s Cortigent presents 6-year results for Orion system at NANS 2026

Vivani Medical (VANI) announced that Cortigent, its wholly-owned subsidiary developing brain implant devices, presented the results of a...

1M ago

VANI

Vivani Medical Announces Equity Offerings to Fund Pipeline

Vivani Medical ( ($VANI) ) has provided an update. On January 25, 2026, Vivani Medical, Inc. priced a...

1M ago

VANI

Vivani subsidiary to present poster on Orion Visual Cortical Prosthesis System

Vivani Medical (VANI) announced that its wholly-owned subsidiary Cortigent will present an poster detailing the technical aspects of...

1M ago

VANI

Vivani Medical’s NPM-139: A Promising Semaglutide Implant with Strong Buy Rating

H.C. Wainwright analyst Yi Chen has reiterated their bullish stance on VANI stock, giving a Buy rating on...

4M ago

VANI

Vivani Medical’s Innovative Semaglutide Implant and Market Positioning Drive Buy Recommendation

Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Vivani Medical, retaining the price target of...

4M ago

VANI

Vivani Medical Reports Q3 2025 Results and Updates

Vivani Medical, Inc. ( ($VANI) ) has released its Q3 earnings. Here is a breakdown of the information...

4M ago

VANI

Vivani Medical Reports Q3 2025 Financial Results

Vivani Medical ( ($VANI) ) has issued an announcement. Vivani Medical reported its financial results for the third...

4M ago

VANI

Vivani Medical reports Q3 EPS (11c) vs (11c) last year

Vivani Chief Executive Officer Adam Mendelsohn, Ph.D., stated, “Vivani achieved significant progress during the third quarter of 2025...

4M ago

VANI

Vivani Medical Announces $15.7M Stock Offering

The latest update is out from Vivani Medical ( ($VANI) ). On October 26, 2025, Vivani Medical, Inc....

4M ago

VANI

Vivani Medical Delays Cortigent Spin-Off Record Date

Vivani Medical ( ($VANI) ) has issued an announcement. On October 3, 2025, Vivani Medical announced the temporary...

5M ago

VANI

Vivani Medical withdraws record date for spin-off of Cortigent

Vivani Medical (VANI) announced that the Company will temporarily withdraw the previously announced record date for the planned...

5M ago

VANI

Vivani Medical’s Strategic Focus and Innovative Product Development Drive Buy Rating

Naz Rahman, an analyst from Maxim Group, reiterated the Buy rating on Vivani Medical. The associated price target...

6M ago

VANI

Vivani Medical Announces Spin-Off of Cortigent

Vivani Medical ( ($VANI) ) has shared an announcement. On September 17, 2025, Vivani Medical announced the record...

6M ago

VANI

Vivani Medical announces spin-off of Cortigent subsidiary

Vivani Medical (VANI) announced that its board of directors has set the record date for the approved spin-off...

6M ago

VANI

VANI FAQ

What was Vivani Medical’s price range in the past 12 months?

Vivani Medical lowest stock price was $0.91 and its highest was $1.92 in the past 12 months.

What is Vivani Medical’s market cap?

Vivani Medical’s market cap is $83.90M.

When is Vivani Medical’s upcoming earnings report date?

Vivani Medical’s upcoming earnings report date is Mar 26, 2026 which is in 19 days.

How were Vivani Medical’s earnings last quarter?

Vivani Medical released its earnings results on Nov 13, 2025. The company reported -$0.11 earnings per share for the quarter, the consensus estimate of -$0.11 by $0.

Is Vivani Medical overvalued?

According to Wall Street analysts Vivani Medical’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Vivani Medical pay dividends?

Vivani Medical does not currently pay dividends.

What is Vivani Medical’s EPS estimate?

Vivani Medical’s EPS estimate is -0.09.

How many shares outstanding does Vivani Medical have?

Vivani Medical has 72,952,230 shares outstanding.

What happened to Vivani Medical’s price movement after its last earnings report?

Vivani Medical reported an EPS of -$0.11 in its last earnings report, expectations of -$0.11. Following the earnings report the stock price went down -11.111%.

Which hedge fund is a major shareholder of Vivani Medical?

Currently, no hedge funds are holding shares in VANI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Vivani Medical Stock Smart Score

Neutral

Fundamentals

Return on Equity

-265.02%

Trailing 12-Months

Asset Growth

-40.06%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Vivani Medical

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.